Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study

Current Medical Research and Opinion

Volumn 15, Issue 1, 1999, Pages 15-24

  Gavras, I ^a   Gavras, H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II antagonists; Angiotensin converting enzyme (ACE) inhibitors; Enalapril; Eprosartan; Essential hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ELECTROLYTE; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; LIPID; NEUROHORMONE; RENIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; TITRIMETRY;

EID: 0032906908     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909115169     Document Type: Article

References (22)

1. Kang, P. M., Landau, A. J., Eberhardt, R. T. and Frishman, W. H. (1994). Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am. Heart J., 127, 1388-1401.
2. Antonios, T. F. T. and MacGregor, G. A. (1995). Angiotensin converting enzyme inhibitors in hypertension: potential problems. J. Hypertens., 13 (Suppl 3), S11-S16.
3. Alderman, C. P. (1996). Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother., 30, 55-61.
4. Israili, Z. H. and Hall, W. D. (1992). Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med., 117, 234-342.
5. Semple, P. F. (1995). Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens., 13 (Suppl 3), S17-S21.
6. Ohlstein, E. H., Brooks, D. P., Feuerstein, G. Z. and Ruffolo, R. R. Jr (1997). Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology, 55, 244-251.
7. Edwards, R. M., Aiyar, N., Ohlstein, E. H., et al. (1992). Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J. Pharmacol. Exp. Ther., 260, 175-181.
8. Elliott, W. (1999). Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J. Hum. Hypertens., in press.
9. Sealey, J. E. (1991). Plasma renin activity and plasma prorenin assays. Clin. Chem., 37, 1811-1819.
10. Bragat, A. C., Blumenfeld, J. and Sealey, J. E. (1997). Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J. Hypertens., 15, 459-465.
11. Fuller, R. W. and Choudry, N. E. (1987). Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. BMJ, 295, 1025-1026.
12. McEwan, J. R., Choudry, N., Street, R. and Fuller, R. W. (1989). Change in cough reflex after treatment with enalapril and ramipril. BMJ, 299, 13-16.
13. Gavras, I. (1992). Bradykinin-mediated effects of ACE inhibition. Kidney Int., 42, 1020-1029.
14. Fuller, R. W., Dixon, C. M., Cuss, F. M. and Barnes, P. J. (1987). Bradykinin-induced bronchoconstriction in humans. Mode of action. Am. Rev. Respir. Dis., 135, 176-180.
15. Coleridge, H. M., Coleridge, J. C., Ginzel, K. H., et al. (1976). Stimulation of irritant receptors and afferent C-fibers in the lungs by prostaglandins. Nature, 264, 451-453.
16. Lacourciere, Y., Brunner, H. R., Irwin, R., et al. (1994). Effect of modulators of the reninangiotensin aldosterone system on cough. J. Hypertens., 12, 1387-1393.
17. Waeber, B., Brunner, H. R., Brunner, D. B., et al. (1980). Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension, 2, 236-242.
18. Mackay, J. H., Arcuri, K. E., Goldberg, A. I., Snapinn, S. M. and Sweet, C. S. (1996). Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch. Intern. Med., 156, 278-285.
19. Ruilope, L. M., Simpson, R. L., Toh, J., et al. (1996). Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood. Press., 5, 32-40.
20. Gavras, H., Liang, C. and Brunner, H. R. (1978). Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. Circ. Res., 43 (Suppl 1), 59-63.
21. Wang, Y-X., Gavras, I., Wierzba, T. and Gavras, H. (1992). Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin-II receptor antagonist, and an angiotensin-converting enzyme inhibitor. J. Lab. Clin. Med., 119, 267-272.
22. Pitt, B., Segal, R., Martinez, F. A., et al. on behalf of the ELITE investigators (1997). Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 349, 747-751.